BioTime, Inc. (NYSEMKT:BTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “

Other analysts also recently issued research reports about the stock. BidaskClub raised shares of BioTime from a “sell” rating to a “hold” rating in a research report on Thursday, September 28th. ValuEngine upgraded shares of BioTime from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $6.50 target price (up previously from $6.00) on shares of BioTime in a research report on Monday, June 19th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. BioTime has an average rating of “Hold” and a consensus target price of $5.33.

Shares of BioTime (BTX) traded up 1.79% during trading on Tuesday, hitting $2.84. The company had a trading volume of 337,361 shares. BioTime has a 12-month low of $2.47 and a 12-month high of $3.97. The stock has a 50-day moving average of $2.77 and a 200 day moving average of $3.04. The stock has a market capitalization of $328.88 million, a price-to-earnings ratio of 4.77 and a beta of 1.37.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Lowers BioTime, Inc. (BTX) to Sell” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/03/zacks-investment-research-lowers-biotime-inc-btx-to-sell.html.

In other news, Director Broadwood Partners, L.P. bought 150,000 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was acquired at an average cost of $2.80 per share, with a total value of $420,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders bought 173,896 shares of company stock valued at $481,220.

A number of hedge funds and other institutional investors have recently bought and sold shares of BTX. Nationwide Fund Advisors increased its stake in BioTime by 2.2% during the 1st quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 939 shares in the last quarter. Family Management Corp raised its holdings in BioTime by 1.4% during the second quarter. Family Management Corp now owns 140,371 shares of the biotechnology company’s stock worth $442,000 after buying an additional 2,000 shares during the last quarter. American International Group Inc. raised its holdings in BioTime by 8.3% during the first quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock worth $137,000 after buying an additional 3,036 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in BioTime by 14.7% during the first quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock worth $199,000 after buying an additional 7,411 shares during the last quarter. Finally, Voya Investment Management LLC raised its holdings in BioTime by 38.3% during the second quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock worth $102,000 after buying an additional 8,996 shares during the last quarter.

About BioTime

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.